Form 8-K - Current report:
SEC Accession No. 0001104659-25-044792
Filing Date
2025-05-06
Accepted
2025-05-06 07:11:55
Documents
14
Period of Report
2025-05-05
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2514089d1_8k.htm   iXBRL 8-K 36307
2 EXHIBIT 99.1 tm2514089d1_ex99-1.htm EX-99.1 12874
  Complete submission text file 0001104659-25-044792.txt   229350

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrsn-20250505.xsd EX-101.SCH 3011
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrsn-20250505_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrsn-20250505_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2514089d1_8k_htm.xml XML 3557
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38129 | Film No.: 25915213
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)